Format

Send to

Choose Destination
Cancer Invest. 2011 Nov;29(9):573-84. doi: 10.3109/07357907.2011.616251. Epub 2011 Sep 19.

Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.

Author information

1
Outcomes Insights, Inc., Westlake Village, CA 91362, USA. bob@outins.com

Abstract

We used Surveillance, Epidemiology, and End Results-Medicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HR] 0.54; 95% Confidence Interval [CI] 0.39-0.74; p < .001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.

PMID:
21929325
PMCID:
PMC3212922
DOI:
10.3109/07357907.2011.616251
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center